6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Replicon plasmids encoding an alphavirus RNA replicase constitute an alternative to conventional DNA plasmids with promise for DNA vaccination in humans. Replicase activity amplifies the levels of transgene mRNA through a copying process involving double-stranded (ds) RNA intermediates, which contribute to vaccine immunogenicity by activating innate antiviral responses. Toll-like receptor (TLR) 3 is a dsRNA innate immune receptor expressed by antigen-presenting dendritic cells (DC). Here, we test the hypothesis that TLR3 is necessary for the immunogenicity of replicon plasmid based DNA vaccines. We show that mouse CD8α + DC phagocytose dying replicon plasmid-transfected cells in vitro and are activated in a TLR3-dependent fashion by dsRNA present within those cells. However, we find that cytotoxic T cell responses to a replicon plasmid intramuscular vaccine are not diminished in the absence of TLR3 in vivo. Our results underscore the potential role of TLR3 in mediating immune activation by dsRNA-bearing replicon plasmid transfected cells and indicate that other innate sensing pathways can compensate for TLR3 absence in vivo.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Toll-like receptor 3 promotes cross-priming to virus-infected cells.

          Cross-presentation of cell-associated antigens plays an important role in regulating CD8+ T cell responses to proteins that are not expressed by antigen-presenting cells (APCs). Dendritic cells are the principal cross-presenting APCs in vivo and much progress has been made in elucidating the pathways that allow dendritic cells to capture and process cellular material. However, little is known about the signals that determine whether such presentation ultimately results in a cytotoxic T cell (CTL) response (cross-priming) or in CD8+ T cell inactivation (cross-tolerance). Here we describe a mechanism that promotes cross-priming during viral infections. We show that murine CD8alpha+ dendritic cells are activated by double-stranded (ds)RNA present in virally infected cells but absent from uninfected cells. Dendritic cell activation requires phagocytosis of infected material, followed by signalling through the dsRNA receptor, toll-like receptor 3 (TLR3). Immunization with virus-infected cells or cells containing synthetic dsRNA leads to a striking increase in CTL cross-priming against cell-associated antigens, which is largely dependent on TLR3 expression by antigen-presenting cells. Thus, TLR3 may have evolved to permit cross-priming of CTLs against viruses that do not directly infect dendritic cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Innate recognition of viruses.

            Virus infection elicits potent responses in all cells intended to contain virus spread before intervention by the adaptive immune system. Central to this process is the virus-elicited production of type I interferons (IFNs) and other cytokines. The sensors involved in coupling recognition of viruses to the induction of the type I IFN genes have only recently been uncovered and include endosomal and cytosolic receptors for RNA and DNA. Here, we review their properties and discuss how their ability to recognize the unusual presence of atypical nucleic acids in particular subcellular compartments is used by the body to detect virus presence.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.

              CD8+ T cell responses can be generated against antigens that are not expressed directly within antigen-presenting cells (APCs), through a process known as cross-priming. To initiate cross-priming, APCs must both capture extracellular antigen and receive specific activation signals. We have investigated the nature of APC activation signals associated with virus infection that stimulate cross-priming. We show that infection with lymphocytic choriomeningitis virus induces cross-priming by a mechanism dependent on type I interferon (IFN-alpha/beta). Activation of cross-priming by IFN-alpha/beta was independent of CD4+ T cell help or interaction of CD40 and CD40 ligand, and involved direct stimulation of dendritic cells. These data identify expression of IFN-alpha/beta as a mechanism for the induction of cross-priming during virus infections.
                Bookmark

                Author and article information

                Journal
                9421525
                8603
                Gene Ther
                Gene Ther.
                Gene therapy
                0969-7128
                1476-5462
                13 October 2008
                04 December 2008
                March 2009
                01 September 2009
                : 16
                : 3
                : 359-366
                Affiliations
                [1 ]Immunobiology Laboratory, Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom
                [2 ]Centre d’Immunologie de Marseille-Luminy, CNRS-INSERM-Université de la Méditerranée, Parc Scientifique de Luminy, Case 906, 13288 Marseille, France
                [3 ]National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892-1502, United States of America
                [4 ]Section of Immunobiology, Yale University School of Medicine and Howard Hughes Medical Insitute, New Haven, CT, USA
                Author notes
                Address correspondence to: Dr. Sandra Diebold, Immunobiology Department, King’s College London, 2 nd Floor Borough Wing, Guy’s Hospital, London SE1 9RT, United Kingdom, Tel: + 44 20 718 81181, FAX: + 44 20 718 83385, E-mail: sandra.diebold@ 123456kcl.ac.uk
                [*]

                These authors contributed equally to this paper

                SSD current address: Peter Gorer Department of Immunobiology, King’s College London, Guy’s Hospital, London SE1 9RT, United Kingdom

                Article
                UKMS2607
                10.1038/gt.2008.164
                2655288
                19052633
                d25fc13e-a095-4794-939e-c7d188f7464c
                History
                Funding
                Funded by: Cancer Research UK :
                Award ID: A3598 || CRUK_
                Categories
                Article

                Molecular medicine
                dendritic cells,toll-like receptors,double-stranded rna,replicon vaccines
                Molecular medicine
                dendritic cells, toll-like receptors, double-stranded rna, replicon vaccines

                Comments

                Comment on this article